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Abstract
The short cytoplasmic tails of the α and β chains of integrin adhesion receptors regulate integrin
activation and cell signaling. Significantly less is known about proteins that bind to α-integrin
cytoplasmic tails (CTs) than β-CTs to regulate integrins. CIB1 was previously identified as an αIIb
binding partner that inhibits agonist-induced activation of the platelet-specific integrin, αIIbβ3. A
sequence alignment of all α-integrin CTs revealed that key residues in the CIB1 binding site on
αIIb are well-conserved, and was used to delineate a consensus binding site (I/L-x-x-x-L/M-W/Y-
K-x-G-F-F). Because the CIB1 binding site on αIIb is conserved in all α-integrins, and CIB1
expression is ubiquitous, we asked if CIB1 could interact with other α-integrin CTs. We predicted
that multiple α-integrin CTs were capable of binding to the same hydrophobic binding pocket on
CIB1 with docking models generated by all-atom replica exchange discrete molecular dynamics.
After demonstrating novel in vivo interactions between CIB1 and other whole integrin complexes
with co-immunopreceipitations, we validated the modeled predictions with solid-phase
competitive binding assays showing that other α-integrin CTs compete with the αIIb CT for
binding to CIB1 in vitro. Isothermal titration calorimetry measurements indicated that this binding
is driven by hydrophobic interactions and depends on residues in the CIB1 consensus binding site.
These new mechanistic details of CIB1-integrin binding imply that CIB1 could bind to all integrin
complexes and act as a broad regulator of integrin function.
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Integrins are a large family of heterodimeric (α/β) transmembrane proteins found in almost
every mammalian cell type. This family consists of 18 α-subunits and 8 β-subunits that can
pair to form 24 different heterodimers. These proteins control many normal cellular
processes including migration, growth, differentiation, and proliferation (1). Integrins also
play significant roles in many diseases including Glanzmann’s thrombasthenia, various
immune disorders, and cancer (2-4). Therefore, examining the details of integrin regulation
and signaling is essential.
A better understanding of the protein-protein interactions occurring at the integrin
cytoplasmic tails (CTs) is necessary to elucidate the details of bidirectional integrin
signaling. While there are well-understood integrin β-subunit binding proteins like talin, the
kindlins, Rab25, PKCα, Src, Numb, and many others (5, 6), there are many fewer known α-
subunit binding partners e.g. Nischarin, Calreticulin, Rab21, p120RasGAP, SHARPIN, and
GIPC1(7-11). We previously reported CIB1 (calcium and integrin binding protein 1) as a
binding partner for the αIIb CT of the platelet-specific αIIbβ3 integrin (12).
CIB1 is a 22 kDa, helical, EF-hand-containing protein related to calcineurin B, and is
expressed in many cell types (13-17). Previous studies revealed that highly conserved
residues N-terminal to the GFFKR motif of the αIIb CT were essential for CIB1 binding
(13, 18). Additionally, multiple reports indicate that CIB1 may modulate either inside-out
(19) or outside-in (20, 21) αIIbβ3 signaling. Besides αIIb, CIB1 binds to a variety of other
proteins including signaling proteins PAK1, Snk, and Fnk (22, 23). While CIB1 is not
required for normal embryonic development (24), potentially because of compensation by
CIB family members CIB2, CIB3, and/or CIB4 (25), CIB1 knockout mice exhibit
phenotypic abnormalities, including impaired pathological angiogenesis, reduced tumor
growth, protection from cardiac hypertrophy, and male sterility (24, 26-28). Here we
examined the physical relationship of the CIB1-integrin interaction in order to gain more
insight into the functional roles of CIB1.
Because CIB1 binds to a conserved region on αIIb, and is ubiquitously expressed, we
hypothesized that CIB1 may bind to other α-integrin CTs. We used molecular docking
simulations to test the plausibility of our hypothesis, and found that αIIb, α5, and αV
cytoplasmic tail peptides dock to the same hydrophobic binding pocket on CIB1. We show
that CIB1 binds to αVβ3 and α5β1 integrins in mammalian cells via co-
immunoprecipitation, demonstrating that CIB1 can interact with different whole integrin
complexes in vivo. We also found that the CT peptides of many integrins, which included
representative members of each receptor subfamily, compete with αIIb for binding to CIB1.
Further, we show that CIB1 binding to all tested α-integrin peptides is driven by
hydrophobic interactions, and that there is a correlation between the hydrophobicity of the
CIB1 binding site on α-integrin CT peptides and binding affinity. These findings indicate
that CIB1 is an even more versatile integrin binding protein than previously realized, and
suggest that CIB1 may play a common role with different integrins.
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Protein purification and peptide synthesis
Human wild type CIB1 was cloned into pProEX HTc (Invitrogen), and further modified to
include an upstream amino-terminal hexahistadine tag followed by a tobacco etch virus
(TEV) cleavage site to facilitate removal of the hexahistadine tag. CIB1 mutants 114IFDF/
AADA, 152LI/AA, and 173F/A were made as previously described (18). Mutant and WT
CIB1 was expressed and purified from E. coli BL21(DE3) as described previously with
slight modifications as follows (14). After harvesting the cells, lysing by sonication, and
centrifugation, clarified cell lysate was loaded onto an AKTA Purifier UPC 100 fitted with a
20 mL His-Prep FF 16/10 column (GE Healthcare). Fractions containing CIB1 were pooled
and dialyzed in storage buffer (50 mM HEPES (pH 7.4), 150 mM NaCl, 10% (v/v) glycerol,
and 100 μM CaCl2). The 6xHis tag was removed by proteolysis using His-tagged TEV,
which was added at approximately 1 mg/100 mg of CIB1 along with 1 mM DTT, and 0.5
mM EDTA. Cleavage was carried out overnight at room temperature. Mature CIB1 was
isolated by subtractive Ni2+ affinity purification, where His-TEV was bound to the column,
and CIB1 was collected in the flowthru. The DTT and EDTA was removed by dialysis in
storage buffer. Protein concentration of mature CIB1 was measured by absorbance at 280
nm and ε = 2980 cm−1 M−1.
Peptides were synthesized by either Bio-Synthesis, Inc. or via the High-Throughput Peptide
Core and Arraying Facility at UNC-CH and purified by high performance liquid
chromatography (HPLC). Peptide mass was confirmed by MALDI MS/MS on a 7400
Proteomics Analyzer (Applied Biosystems). Sequences used are listed in Table S1.
To generate cytoplasmic tails that could be precipitated with amylose resin beads, DNA
encoding either residues 1014-1039 of human wild type αIIb, or residues 1011-1048 of
human wild type αV was cloned into a pMAL vector (New England Biosystems)
downstream of the malE gene. The fusion protein-encoding vectors were transformed into E.
coli BL21Star(DE3), which were then grown at 37°C in 1 L of LB, and 1mM IPTG was
added to induce over-expression of the MBP-α-integrin CT fusion proteins, which continued
for 4 hours at 37°C. The cultures were harvested by centrifugation, resuspended in 50 mM
HEPES (pH 7.4), 150 mM NaCl, lysed by sonication, and then clarified by centrifugation.
The MBP fusion products were purified from the lysates amylose resin beads (New England
Biolabs) according to the manufacturer’s instructions. Samples were dialyzed against 50
mM HEPES (pH 7.4), 150 mM NaCl, 10% (v/v) glycerol overnight, tested for purity by
SDS PAGE, and final protein concentration was measured using the BCA protein assay
(Pierce).
All-atom replica exchange discrete molecular dynamics (DMD)
Modeling of CIB1 binding to α5 and αV cytoplasmic tail peptides was performed to test for
potential binding interactions with CIB1, and those models were compared to a simulation
of αIIb binding to CIB1. The model of CIB1 used in the simulations was either a homology
model of CIB1 based on the ligand-bound form of calcineurin B (PDB code: 1DGU) or the
solution structure of αIIb-CT-bound CIB1 (PDB code: 2LM5) (29). The structure of αIIb
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was taken from (PDB code: 2KNC), and α5 and αV peptide structures were modeled after
the αIIb structure using I-TASSER (30, 31). The starting structure of each integrin peptide
was placed approximately 40 Å away from CIB1 using the edit functions of PyMol (32).
The DMD simulations were performed as described by Dagliyan, et al. (33). In these
simulations the backbone of CIB1 was fixed while all atoms of the peptides were free to
move with some constraints added to preserve the secondary structure. The DMD engine
approximates inter-atomic interactions by discrete square well potentials, and models
proteins using the united atom representation. The Van der Waals forces, solvation
interactions, and electrostatic interactions are modeled in a discretized manner as well. In
replica exchange, a simulation is performed in replicate at different temperatures and the
structures are exchanged between the replicates at regular intervals. This robust approach
allows the engine to more easily overcome energy barriers. The length of each simulation
was 106 time units, which is approximately 50 ns of real time. After the DMD simulations
were complete, hierarchical clustering of the integrin-binding conformations, or poses
representing a single instantaneous posture captured during the simulation, were performed
using root-mean-square distances (RMSD) calculated over all heavy atoms in the peptide,
and MedusaScore was used to evaluate the energy landscape of the clustered poses (34). The
lowest energy complexes were taken from the largest clusters and further refined using
MedusaDock to obtain the final structures (35). Images of the models were created using
PyMol. Atom pair contacts made between CIB1 and the integrin CT peptides were identified
in the docking models by finding all residues on CIB1 that were within 4 Å of any side
chain atom on the integrin CT peptide using PyMol.
Co-immunoprecipitation (co-IP)
Co-IP was performed to determine whether CIB1 associates with αVβ3 or α5β1 integrin
complexes in mammalian cells as previously described with some modifications (19).
HEK29-T cells were maintained in DMEM supplemented with 10% FBS and 1% non-
essential amino acids at 37°C and 5% CO2. Plasmids encoding human integrin α5 or αV
were transiently transfected in HEK293T cells using Fugene (Roche) according to
manufacturer’s instructions. Cells were harvested and lysed with CHAPS lysis buffer (25
mM HEPES [pH 7.4], 150 mM NaCl, 10 mM CHAPS, 30 mM NaF, 10 mM β-
glycerophosphate, 0.2 mM Na3VO4, 1.25 mg/mL N-ethylmaleimide, 0.1 mM CaCl2, 0.1
mM MgCl2, 5% glycerol, and Protease Inhibitor Cocktail III (Calbiochem) diluted 1:100).
Clarified lysates were incubated overnight with either chicken non-specific or anti-CIB1
IgY, and immune complexes were precipitated using goat anti-chicken IgY agarose beads
(Aves Labs, Inc.). Beads were washed three times in lysis buffer and eluted with 1X non-
reducing sample buffer. Samples were resolved by SDS-PAGE, transferred to PDVF
membrane and immunoblotted with rabbit anti-integrin α5 polyclonal antibody (Millipore),
mouse anti-integrin αV monoclonal antibody (BD Transduction) or chicken anti-human
CIB1 IgY.
Co-precipitation assay
Purified recombinant MBP-αIIb or MBP-αV cytoplasmic tails were loaded onto amylose
resin beads and washed 3x in assay buffer (25 mM HEPES, pH 7.4, 150 mM NaCl, 0.1 mM
CaCl2). MBP-tail beads were added to recombinant WT or mutant CIB1 proteins diluted in
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assay buffer (0.75 mg/ml) and incubated 1 h at 4°C. Beads were washed 3x with assay
buffer and samples were analyzed by SDS-PAGE.
Solid-phase binding assays
Competitive inhibition solid-phase binding assays were performed to measure CIB1 binding
to multiple α-integrin cytoplasmic tail (CT) peptides. Various α-integrin CT peptides were
immobilized in 96-well plates. Increasing concentrations of soluble peptides were used to
compete with the immobilized peptide for CIB1 binding. Immulon 1B 96-well plates (Fisher
Scientific) were coated with 50 μL of 50 μM peptide solutions, which were incubated
overnight at room temperature (all subsequent incubations were performed at room
temperature). Empty and peptide-coated wells were blocked with 3% BSA (bovine serum
albumin) in PBS (phosphate-buffered saline). CIB1 (between 0.05 and 0.1 μM final
concentrations) was mixed with various concentrations of soluble peptide in 50 mM HEPES
(pH 7.4), 150 mM NaCl, 0.1 mM CaCl2, 0.1 mM MgCl2, and added to microtiter wells in a
final volume of 50 μL/well. Solutions were discarded and the wells were washed thrice with
200 μL of 0.05% Tween in Tris-buffered saline, pH 7.4 (TBS-T); all subsequent incubations
were preceded by similar washing steps. To detect CIB1 binding, chicken anti-CIB1-IgY
was added and incubated 1 h followed by addition of HRP-conjugated donkey anti-chicken -
IgG (Jackson ImmunoResearch). To visualize antibody binding, SigmaFAST o-
phenylenediamine (OPD) solution (Sigma) was added and the reaction allowed to proceed
for at least 10 min. The reaction was terminated by addition of 4N H2SO4 and absorbance
was measured at 490 nm in a 96-well microplate reader (Spectramax M5).
Isothermal titration calorimetry (ITC)
ITC was performed to quantify the thermodynamics of binding between CIB1 and α-
integrin tail peptides as previously described with minor modifications (13). Purified CIB1
was dialyzed extensively in 50 mM HEPES (pH 7.4), 150 mM NaCl, 0.1 mM CaCl2 (unless
noted differently elsewhere), and diluted to a concentration of 100 μM. Peptides were
freshly dissolved to concentrations ranging from 0.8 to 1 mM in the same buffer as CIB1.
Isothermal titrations were performed using a MicroCal VPITC microcalorimeter. Injections
of 10 μL of peptide were added at 300 s intervals at either 15° C or 26° C. The heats of
dilution were estimated from injections made after saturation occurred. These values were
subtracted from the data before one-site curve fitting was performed using Microcal, LLD
Origin 7. The stoichiometry (N), association and dissociation constants (Ka, Kd), and
enthalpy change (ΔH) were obtained directly from the data, and the Gibbs free energy
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Sequence conservation of α-integrin cytoplasmic tails (CTs)
The C-terminal sequences of several α-integrin subunits were aligned to assess the
likelihood that CIB1 could bind to other integrins besides αIIb. The alignment in Fig. 1
shows several highly conserved residues in the membrane-proximal region of the integrin
tails, revealing a consensus motif of I/L-x-x-x-L/M-W/Y-K-x-G-F-F. The consensus
sequence is conserved in all 18 α-integrin CTs (Fig. S1). This observation led us to
hypothesize that CIB1 can bind to most other integrins, and potentially contribute to their
signaling pathways. Each α-integrin CT shown in Fig. 1 was tested for binding to CIB1. We
selected a functionally diverse subset of α-integrins that included αV, the only other β3
integrin partner, the ubiquitous fibronectin receptor, α5, which binds to the R-G-D
sequence, and some commonly observed representatives from other receptor subclasses; a
laminin receptor (α3), a collagen receptor (α2), leukocyte-specific receptors (αM and αL),
and a non-RGD fibronectin receptor (α4) (1).
Docking of α-integrin CTs to CIB1
We attempted to identify the most likely integrin binding site on CIB1 using replica-
exchange discrete molecular dynamics (DMD) simulations (Fig. 2A). The starting CIB1
structure, a homology model to Calcineurin B (PDB code 1DGU), was chosen because it has
the C-terminal helix of CIB1 displaced, which is a key mechanism in integrin binding by
CIB1 (36, 37). This model of CIB1 was sufficient for the purposes of qualitatively assessing
the likelihood of CIB1 interacting with multiple integrins. Representatives of the most
frequently sampled conformations from the lowest energy clusters of these simulations
indicate a significant overlap in the binding sites occupied on CIB1 by each α-integrin CT
tested (Fig. 2B). Furthermore, the integrin residues that were close enough to contact CIB1
included at least the first three N-terminal hydrophobic residues of each integrin peptide.
The GFFKR motifs were only involved in the binding interfaces of αIIb and αV, with both
Phe1023-1024 residues in αIIb contacting CIB1, and only Phe1020 of αV making contact. As a
consequence of the sequence variation of the α-integrin CTs and the randomized sampling
of the simulation, the number of atom pair contacts formed between CIB1 and each α-
integrin CT varied; αIIb, α5, and αV appeared to contact 9, 5, and 12 residues on CIB1
respectively.
Association of CIB1 with αVβ3 and α5β1 integrins in mammalian cells
Because we predicted that CIB1 could bind to α5 and αV integrins in simulations, we asked
if we could detect CIB1 binding to integrins in cells via co-immunoprecipitation assays.
Endogenous CIB1 was immunoprecipitated from HEK293T cells overexpressing either
integrin α5 or integrin αV (Fig. 2C), and both integrins co-precipitated with CIB1.
Competitive binding of α-integrin CT peptides to αIIb binding site of CIB1
Because molecular docking suggests that α5 and αV peptides can bind to sites overlapping
that of αIIb, we tested the ability of various α-integrin CTs (see Table S1) to compete with
αIIb CT peptide for CIB1 binding in competitive solid-phase binding assays. Most solution-
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phase integrin peptides dose-dependently inhibited CIB1 binding to αIIb CT peptide (Fig.
2D). The IC50 ± 95% CI of αIIb, α2, α5, αL, and αV was 9.6 ± 1.1, 6.0 ± 4.0, 8.3 ± 1.3,
19.7 ± 6.7, and 2.7 ± 1.3 respectively. The relatively weak competitive inhibition of CIB1
binding by αM, α3, and α4 CT peptides was not sufficient to determine IC50 values.
Effect of integrin N-terminal CT residues on CIB1 binding
Previous data show that the hydrophobic N-terminal residues on the αIIb CT peptide are
important for binding to CIB1 (18). We therefore asked if changing residues in this region of
αV would similarly disrupt binding to CIB1. CIB1 binding to αV peptides with either four
or six alanine substitutions at the N-terminus (αV-4A, and αV-6A respectively) was
compared to CIB1 binding to αV-WT via ITC (Fig. 3A-C). While αV-WT binds to CIB1
endothermically with a 1:1 stoichiometry and a Kd of 4.3 μM, isothermal data for αV-4A
and αV-6A appear to have been generated solely from heats of dilution of the peptides, and
we could not reliably fit these data to any standard binding models.
Effect of mutating residues in CIB1 hydrophobic pocket on integrin-binding
We used previously generated CIB1 mutants shown to inhibit binding to αIIb to determine if
these mutations could also inhibit binding of different integrins (18). These mutated residues
are also a part of the hydrophobic binding surface on CIB1, and formed atom pair contacts
with the integrin peptides in the docking simulations. We tested binding of CIB1
mutants, 152LI/AA, 114IFDF/AADA, and 173F/A to fusion proteins, MBP-αIIb CT and
MBP-αV CT (Fig. 3D). The western blots show that all tested CIB1 mutations differentially
affect binding to distinct integrins. Notably, mutation of CIB1 residues 152LI/AA and 173F/A
significantly reduced CIB1 binding to the αIIb CT fusion protein, whereas mutation
of 114IFDF/AADA residues significantly reduced binding to the αV CT fusion protein.
The role of hydrophobic interactions in CIB1 binding to α-integrins
To further characterize the mechanism of binding between CIB1 and α-integrin CTs, we
used isothermal titration calorimetry (ITC) to measure the binding thermodynamics between
CIB1 and additional α-integrin CT peptides. The binding data show a stoichiometry of 1:1
with μM binding affinities between CIB1 and all α-integrin peptides tested (Table 1, Fig.
S2), which is consistent with previously measured binding affinities between CIB1 and αIIb
(13, 38-40). In contrast to the competitive ELISA results where neither α3 nor αM competed
effectively with immobilized αIIb for CIB1 binding (Fig. 2D), ITC results indicated that the
α3 and αM CT peptides do bind CIB1, albeit with significantly lower affinities than αIIb.
While the binding affinities of the weakest CIB1-binding peptide and the strongest vary by
an order of magnitude, the thermodynamic characteristics are similar. With the exception of
the exothermic binding exhibited by CIB1 binding to the αIIb CT peptide, CIB1 binding to
all other peptides was endothermic. The thermodynamic profiles of CIB1 binding to the
various α-integrin CT peptides suggest that the CIB1-integrin interaction is mainly driven
by hydrophobic interactions (Fig. 4A) (41). Overall, CIB1 bound to α-integrin CTs with
similar stoichiometry, affinity, free energy, and entropy.
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Correlation between hydrophobicity of N-terminal CT amino acids and CIB1-integrin
binding affinity
We reexamined the α-integrin peptide sequences to identify potential factors that may
explain why there was some variance in CIB1 binding thermodynamics, and determined that
the most sequence variance within the CIB1 binding region occurred among the N-terminal
residues (Fig. 4B). Given the potential variability in CIB1-integrin atom-pair contacts and an
apparently dominant role played by hydrophobic interactions in CIB1-integrin binding, we
asked if there was a relationship between the hydrophobicity of the N-terminal membrane
proximal region of the integrins and CIB1 binding affinity. We used the empirically-defined
Wimley-White water-octanol scale (where more negative values indicate greater
hydrophobicity) to calculate the total side-chain hydrophobicity of the highly varied
membrane-proximal residues (the second through fourth residues) of each α-integrin CT
peptide tested (42). Linear regression of the data reveal a negative correlation between the
total hydrophobicity of the highly varied region of the α-integrin peptides and the CIB1
binding affinity measured by ITC, with a slope of −1.7 ± 0.5 and R2 = 0.72 (Fig. 4B). The
calculated hydrophobicities in the highly varied region of all α-integrin CTs are within the
range (−3.62 to +1.25 kcal/mol) of the tested set of α-integrin CTs (Fig. 4C).
DISCUSSION
Because integrin function is regulated by cytoplasmic tail-binding proteins, and the potential
regulatory roles played by α-integrin binding proteins have been less studied than β-integrin
binding proteins, we explored the α-integrin binding capabilities of CIB1. CIB1 is
ubiquitously expressed, and interacts with a region of the platelet-specific integrin αIIb
cytoplasmic tail that is well-conserved in all α-integrins. These observations suggested that
CIB1 can bind to other α-integrins.
To quickly assess the feasibility of testing the hypothesis that CIB1 binds to other α-integrin
CTs, we used discrete molecular dynamics (DMD) simulations, which have been
successfully employed in various capacities to obtain accurate estimates of protein-peptide
interactions using only structural data of the receptor and ligand as input (33, 43). The
docking simulations showed structural details of CIB1 binding to αIIb, α5, and αV CT
peptides, and a comparison to the recent CIB1-αIIb complex structure (15) validated that
these simulations produced plausible models. The interaction interface predicted by the
docking simulations was supported by mutational analysis where CIB1 mutants in the
hydrophobic binding surface selectively affected binding to different integrins, and Ala
substitutions in integrin peptides disrupted binding to CIB1. The positive results from the
simulations not only suggested that CIB1 can bind to multiple α-integrins, but that multiple
integrins bind to the expected hydrophobic surface on CIB1. This result led us to test
whether or not CIB1 could actually bind to multiple integrins in cells. We therefore co-
immunoprecipitated whole integrins; the results validated that CIB1 can bind to other
integrins in cells, as it does αIIbβ3 (13). Furthermore, competitive binding experiments
showed that several α-integrin CT peptides compete with the αIIb CT for CIB1 binding,
which supported the simulation data that integrins bind to the same general region on CIB1.
Interestingly, integrins α3, αM, and α4, which have sequences least similar to αIIb,
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competed poorly with αIIb for CIB1 binding. As expected, ITC measurements showed that
the binding affinity of αM may not be strong enough to compete with αIIb under the tested
conditions. In contrast, the CIB1 binding affinities for α3 and α4 are likely strong enough to
compete with αIIb, if competition is for the same binding site. This supports a possibility
raised by docking simulations that different integrins may bind to different local binding
sites within the same pocket on CIB1. Further, the possibility of integrins binding to
different binding sites within the hydrophobic binding pocket of CIB1 was supported by in
vitro co-precipitation assays using various CIB1 mutants and MBP-integrin CT fusion
proteins. Three different sets of CIB1 mutations differentially affected CIB1 binding to two
different α-integrins, suggesting that while integrins may bind within the same binding
pocket, the specific molecular contacts are different. Furthermore, mutations in CIB1 around
the Mg2+/Ca2+ binding site in EF-hand III that were previously shown not to affect αIIb
binding (44), did affect αV binding. This localized specificity may explain how CIB1 is able
to bind to many different integrins using the same binding pocket. This dynamic binding
capacity of CIB1 may also be heavily influenced in vivo by Mg2+ and Ca2+ concentrations,
which have dramatic effects on CIB1 structure and binding affinity (16, 36, 37, 40, 44).
In addition to identifying the integrin-binding site on CIB1, we also validated that the highly
conserved membrane-proximal region of α-integrin CTs is the CIB1 binding site.
Substituting alanine residues for a series of N-terminal residues in the αV CT peptide
abolished binding to CIB1, which is in agreement with previous reports that these residues
are important for CIB1 binding to αIIb (18). We can therefore infer that these hydrophobic
residues in the consensus binding sequence are essential for CIB1 binding to all α-integrin
CTs. Moreover, we have shown that there is a correlation between the total side-chain
hydrophobicity of residues in this region and CIB1 binding affinity. Even though binding
affinity increases as the total side-chain hydrophobicity in this region decreases, the least
hydrophobic peptide, αM, had the weakest binding affinity. This indicates that an optimum
range of hydrophobicities of these residues coincides with a stronger binding affinity to
CIB1. Based on this observed relationship, we calculated the hydrophobicities of the highly
varied region of the consensus motif in all α-integrins. Because the test set includes
representative members of each integrin subfamily, and all of the calculated
hydrophobicities fall within the range of the tested integrins, we conclude that the strength
of CIB1 binding to all α-integrins can be categorized as moderate if the highly varied region
is hydrophobic or weak if this region is hydrophilic. These hydrophobicity data do not,
however, explain why αIIb exhibits exothermic binding, while the other peptides exhibit
endothermic binding. We suspect that the Ala in the fourth position of the αIIb peptide is
necessary, but not sufficient to cause this difference in enthalpy. This is evidenced in part by
the Ala substitutions made in the αV peptides where the enthalpy of binding to CIB1 goes
from endothermic with the WT peptide to exothermic with the 4-Ala peptide. We believe
that this is not sufficient, however, because αM, which has an Ala in the same position
exhibits endothermic binding. Further testing is required to clarify how the integrin sequence
affects the thermodynamic properties of binding to CIB1.
To gain greater insight into the binding mechanism and biological potential of CIB1, we
measured the binding thermodynamics between CIB1 and several α-integrin CT peptides.
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We were surprised to find that the enthalpies of binding between CIB1 and the newly tested
α-integrin sequences differed from that of αIIb, yet the binding affinities were relatively
similar to one another. This may indicate that there is an αIIb-specific binding mechanism,
which begs the question of whether different binding mechanisms correlate with different
functional roles. Previous evidence indicated that CIB1 plays a role in inside-out integrin
signaling by negatively regulating αIIbβ3 activation in thrombin-stimulated megakaryocytes
(19), and contributes to outside-in signaling by regulating cell spreading through focal
adhesion kinase (FAK) (20, 21). Whether CIB1 plays similar roles with other integrins, or
different roles, as potentially implied by its distinct thermodynamic binding properties with
other integrins, is currently unknown but will be of interest for future studies.
In conclusion, we present data that CIB1 binds to seven additional α-integrin CT peptides,
bringing the total number of α-integrins that can associate with CIB1 to eight. Because some
α-integrins may form heterodimers with multiple β-integrins (e.g., αVβ1, αVβ3), we infer
that the total number of integrin complexes with which CIB1 interacts is 13. Based on
sequence comparisons of the cytoplasmic membrane-proximal regions of the remaining 10
α-integrin subunits, we predict that CIB1 could bind to all 24 known integrin heterodimers.
These findings suggests that CIB1 may be a much broader regulator of integrin function
than previously realized. Additionally, broad integrin-binding activity is potentially
conserved across CIB family proteins as indicated by the finding that CIB2 binds to α7 and
αIIb (45, 46). Because this study suggests that CIB1 may act as a broad regulator of integrin
function, and recent evidence revealed that CIB1 plays a vital role in cancer cell survival
(47), it is important to further investigate mechanistic and functional details of CIB1-integrin
interactions.
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A) Sequence alignment of select α-integrin tails. The minimum CIB1 binding sequence of
integrin αIIb is boxed. Asterisks denote residues in αIIb that are critical for binding to CIB1.
B) The consensus logo (generated at http://weblogo.berkeley.edu/), where bits indicate the
level of conservation at a position, and letter size indicates the frequency of observing a
given residue at a given position.
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α-integrin binding site of CIB1. A) Lowest energy structures from molecular docking of α-
integrin peptides (yellow cartoons) to CIB1 gray surface. Integrin peptide is indicated in
each panel. Residues close enough to contact each peptide are colored on CIB1 surface
model. B) Overlay and close-up of integrin-binding residues on CIB1 determined from
docking with αIIb (magenta sticks), α5 (green sticks), and αV (orange sticks). C)
Immunoprecipitates and whole cell lysates (WCL) from HEK293T cells overexpressing
either integrin α5 or αV were lysed and immunoprecipited with either control IgY or anti-
CIB1 IgY, and immunoblotted with anti-integrin α5 (upper) or anti-integrin αV (lower),
while CIB1 was detected by immunoblotting with an anti-CIB1 antibody. Irrelevant lanes
between the immunoprecipitate and WCL lanes were excluded by cropping the images. D)
Competitive inhibition binding assays were used to test the binding of CIB1 to eight α-
integrin tail peptides. CIB1 binding (y-axis), as measured by absorbance of OPD (o-
phenylenediamine) at 490 nm, and normalized to A490 at the lowest peptide concentration
(A0) is compared to increasing concentrations of a given solution-phase α-integrin peptide
(x-axis). Data points represent mean ± SEM (N=2), and fit with a dose-response curve.
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Validation of interaction sites predicted by DMD. Isotherms (upper) and integrated peaks fit
with one site binding model (lower) of A) αV-WT, B) αV-4A, and C) αV-6A. Data of
αV-4A and αV-6A do not reasonably fit any standard binding models. D) CIB1 co-
precipitation with MBP-αIIb CT and MBP-αV CT. Various CIB1 mutants, indicated above
the lanes and highlighted (black) on the structure to the right, were tested for their ability to
bind to α-integrin CTs.
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CIB1 binds to α-integrin CTs through hydrophobic interactions. A) Thermodynamic profiles
of CIB1 binding to α-integrins. The free energy ΔG (solid), enthalpy ΔH (checkered), and
entropy TΔS (shaded) are plotted for CIB1 binding to the α-integrin CTs shown on the x-
axis. The thermodynamic profiles indicate which types of interactions, HB (hydrogen-
bonding) or HI (hydrophobic interactions) drive binding. B) N-terminal hydrophobicity of
α-integrin CT peptides correlates to CIB1 binding affinity. The CIB1 binding affinity of
each α-integrin CT as determined by ITC (y-axis) is compared to the total hydrophobicity of
the region indicated in the consensus logo below plot (residues 2-4) of each peptide (●).
Data were fit with a linear regression model (R2 = 0.72). The value of αM (⊗) was excluded
from the regression as an outlier using the ROUT method of Graphpad Prism 5 with
threshold Q = 1.0%. C) Hydrophobicity of residues 2-4 of each α-integrin CT peptide
ranked in order of most hydrophobic to least.
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Table 1
ITC of CIB1 and α-integrin cytoplasmic tail peptides. Representative titration isotherms are shown in Fig. S2.
Errors shown are from fitting the ITC data to a one-site model. Errors are not shown for TΔS or ΔG as those
are calculated values.
Integrin N Kd (μM) ΔH (kJ/mol) TΔS (kJ/mol) ΔG (kJ/mol)
αIIb 0.9 ± 0.0 1.4 ± 0.1 −16.4 ± 0.1 17.1 −33.4
αIIba 1.2 ± 0.0 3.1 ± 1.8 −34.1 ± 2.2 −2.4 −31.7
α2 1.1 ± 0.0 0.9 ± 0.3 5.0 ± 0.2 39.7 −34.6
α3 1.0 ± 0.0 5.1 ± 1.0 4.2 ± 0.1 34.6 −30.4
α4a 0.8 ± 0.0 0.4 ± 0.1 32.7 ± 0.5 67.9 −35.2
α5 0.9 ± 0.0 6.9 ± 0.4 21.4 ± 0.3 50.7 −29.3
αL 1.1 ± 0.0 3.2 ± 0.6 8.2 ± 0.4 39.5 −31.3
αM 1.1 ± 0.0 23.6 ± 1.4 8.8 ± 0.2 35.2 −26.4
αV 0.9 ± 0.0 4.3 ± 0.9 7.3 ± 0.4 38.0 −30.7
αV-4Ab N.D. >100 μM N.D. N.D. N.D.
αV-6Ab N.D. >>100 μM N.D. N.D. N.D.
a
ITC of α4 was performed in ITC buffer without any NaCl due to peptide solubility issues. αIIb binding to CIB1 was also tested in the absence of
NaCl with insignificant effects on the binding affinity. However, the thermodynamic properties suggest a change in the mechanism of binding.
b
N.D. = Not determinable. The CIB1 binding affinities of these ligands must be greater than the upper limit of detection for ITC (100 μM).
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